Chembio Diagnostics (CEMI) to Acquire RVR Diagnostics

November 4, 2016 5:53 AM EDT
Get Alerts CEMI Hot Sheet
Trade CEMI Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Chembio Diagnostics, Inc. (Nasdaq: CEMI) announced the Company has entered into an agreement to acquire RVR Diagnostics Sdn Bhd (RVR), a Malaysian, privately-held manufacturer and distributor of POC diagnostic tests for infectious diseases. Under the terms of the agreement, Chembio will pay up to US$1.5 million in cash and up to US$2 million in Chembio stock, based on the achievement of certain milestones, and Chembio also will forgive US$250,000 currently owed by RVR to Chembio. The transaction, which is subject to completion of certain due diligence and other matters, is expected to close during the first quarter of 2017, at which time RVR will become a wholly-owned subsidiary of Chembio.

In 2014, Chembio and RVR entered into two agreements through which RVR acquired rights to license, manufacture and distribute certain Chembio products, including exclusive distribution rights for Chembio's DPP® HIV 1/2 Assay and DPP® HIV-Syphilis Assay in Southeast Asia. Since entering into these agreements, RVR has achieved a number of important milestones, including:

  • completed construction of a state-of-the art manufacturing facility, capable of producing Chembio’s DPP® Assays, and obtained ISO 13485 certification;
  • provided funding to accelerate the development of Chembio's DPP® Dengue Assay, which is expected to be launched in Southeast Asia during the fourth quarter of 2016;
  • received regulatory approval to market and sell products in a number of Southeast Asia countries, under both RVR and Chembio brands;
  • obtained a key tender award in Malaysia and initiated product sales into Southeast Asia, which RVR expects to result in 2016 revenue in excess of US$1.5 million.

Considering the progress made by RVR, the acquisition of RVR provides Chembio with additional revenue, as well as a strategically located and cost-effective manufacturing facility that will be important in serving a number of global markets, including the rapidly growing Asian markets.

John Sperzel, Chembio's CEO, commented, "Our growth plans include expansion into the Asia Pacific region, and we believe a corporate presence in Malaysia, which is centrally located in Southeast Asia, will be a key success factor. The RVR team has made excellent progress to establish a high-quality, low-cost manufacturing facility, which recently obtained ISO 13485 certification. We believe the combination of RVR’s cost-effective manufacturing competence and Chembio’s patented DPP® technology will allow Chembio to accelerate product registrations within Southeast Asia, where the population exceeds 600 million, and, also to build a stronger presence in other regions."

Mac Vajuram, RVR’s Managing Director, commented, "We established RVR with the goal of becoming a leading supplier and distributor of high quality point-of-care diagnostic products in Asia. Since its inception, RVR has been capitalized with a combination of the founders' investments, public grants and research support from the National University of Malaysia, the country's premier university. Our partnership with Chembio, and our presence in Malaysia, has positioned RVR for success, and we believe this transaction will create additional growth opportunities in Asia and other markets.”



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, Management Comments, Mergers and Acquisitions

Related Entities

Definitive Agreement

Add Your Comment